ProfileGDS5678 / 1431302_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 83% 83% 86% 85% 84% 85% 84% 88% 88% 87% 84% 88% 84% 85% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.0523283
GSM967853U87-EV human glioblastoma xenograft - Control 26.0977283
GSM967854U87-EV human glioblastoma xenograft - Control 36.4863886
GSM967855U87-EV human glioblastoma xenograft - Control 46.6040685
GSM967856U87-EV human glioblastoma xenograft - Control 56.2811784
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.1692285
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.0694684
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.8081288
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.8196388
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.7055987
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.1685184
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.8445888
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.2005184
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.3581385